We are looking for self-funded students or students who have secured funding from an independent body. The successful applicant will be expected to provide the funding for tuition fees (check University of Liverpool website), consumables fee (£15000 per annum) and living expenses during their stay in Liverpool.
(1) Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in haematological malignancies. Al-Zebeeby A., Vogler M., Milani M., Richards C., Alotibi A., Greaves G., Dyer MJS., Cohen GM. & Varadarajan S. Haematologica, Epub. doi:10.3324/haematol.2018.204701
(2) BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL. Greaves G., Milani M., Butterworth M., Carter RJ., Byrne DP., Eyers PA., Luo X., Cohen GM. & Varadarajan S. Cell Death and Differentiation, Epub. doi: 10.1038/s41418-018-0183-7
(3) BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells. Butterworth, M., Pettitt, A., Varadarajan, S. & Cohen, G. M. British Journal of Cancer, 114(6), 638-641. doi: 10.1038/bjc.2016.49